文献速递淋巴瘤

来那度胺维持治疗对R-CHOP缓解的弥漫大B细胞淋巴瘤患者的生活质量、剂量与安全性:REMARC随机对照研究结果

Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study.
PubMed 文献 · Br J Haematol · 2019-11-08

REMARC研究亚组分析纳入457例经R-CHOP诱导缓解的老年弥漫大B细胞淋巴瘤患者,评估来那度胺维持治疗对健康相关生活质量的影响。来那度胺组与安慰剂组在随机化时及维持期间全球健康状况评分相似,来那度胺未对生活质量产生负面影响,且无论是否减量无进展生存均优于安慰剂。

要点

  • 来那度胺维持治疗未显著改变全球健康状况、躯体功能或疲劳评分
  • 可观察的不良事件更常见且更易导致减量,但减量不影响无进展生存获益
  • 来那度胺维持治疗在不良事件增加的情况下仍不损害生活质量

核心结论

  • 来那度胺维持治疗延长了弥漫大B细胞淋巴瘤患者的无进展生存期,且未对健康相关生活质量产生负面影响。

研究设计与样本

  • REMARC研究为3期随机对照试验,本分析纳入457例经R-CHOP诱导化疗缓解的老年弥漫大B细胞淋巴瘤患者,来那度胺组229例,安慰剂组228例。

主要发现

  • 来那度胺组患者的全球健康状况、躯体功能和疲劳评分无有意义变化。
  • 无论是否减量,来那度胺组的无进展生存期均优于安慰剂组。

关键数值与推荐

  • 全球健康状况评分采用欧洲癌症研究与治疗组织生活质量问卷-C30第3.0版评估。
  • 不良事件事后分类为主观(患者可感知)或可观察(仅医生可测量)。

临床怎么用

  • 对于经R-CHOP诱导缓解的老年弥漫大B细胞淋巴瘤患者,可考虑来那度胺维持治疗以延长无进展生存,且不必担心生活质量受损。
  • 可观察的不良事件更易导致减量,但减量不影响无进展生存获益,临床可据此管理毒性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Lenalidomide maintenance therapy prolonged progression-free survival (PFS) versus placebo in elderly patients with diffuse large B-cell lymphoma (DLBCL) responding to induction chemotherapy in the phase 3 REMARC study. This subpopulation analysis assessed the impact of lenalidomide maintenance and treatment-emergent adverse events (TEAEs) on health-related quality of life (HRQOL). Global health status (GHS), and physical functioning and fatigue subscales were evaluated in patients who completed the European Organisation for Research and Treatment of Cancer quality-of-life questionnaire-C30 v3.0. The impact of TEAEs classified post hoc as subjective (patients can feel) or observable (only measurable by physicians) on dose reductions and discontinuations was assessed. Among 457 patients (lenalidomide, n = 229; placebo, n = 228), mean (standard deviation) GHS was similar between treatment arms [68·2 (20·7) Versus 72·0 (17·8)] at randomisation and remained similar during maintenance. Patients receiving lenalidomide experienced no meaningful changes in GHS, physical functioning, or fatigue. Observable TEAEs were more common (81·1% Versus 66·3%) and more likely to lead to dose reductions, than subjective TEAEs in both arms. PFS was superior in the lenalidomide arm regardless of dose reduction. Lenalidomide maintenance prolonged PFS and did not negatively impact HRQOL in patients with DLBCL despite TEAEs being more common, when compared with placebo.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Thieblemont C, Howlett S, Casasnovas RO, et al. Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study. Br J Haematol. 2019. PMID: 31702836. doi:10.1111/bjh.16300

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。